Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
is pivoting to anti-obesity therapies as patents for the blockbuster medications start to expire, unleashing a wave of generic supply for the global weight-loss market thats expected to touch $100 billion by 2030
Eli Lillys revenues grew by 32% year over year in 2024 as Zepbound and Mounjaro drove volume growth
They've received a lot of attention, and for good reason
.webp)
Novo Nordisk initiated large clinical trials to evaluate semaglutide, a drug initially developed for diabetes, in individuals with early Alzheimers disease (van der Flier Wiesje M
Mol Pharmacol 82: 10661073
US$ 20.29
US$ 27.85
US$ 28.19
US$ 24.64
